The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus").

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

There are many types of liver disease, ranging from those that are treatable to those that require a liver transplant. Learn about symptoms, causes, and more.